Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER+ HER2- Advanced Breast Cancer”

242 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 242 results

Early research (Phase 1)Looking for participantsNCT04872166
What this trial is testing

BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Who this might be right for
Advanced Solid TumorMetastatic Breast Cancer
Edgewood Oncology Inc. 112
Testing effectiveness (Phase 2)Study completedNCT02491983
What this trial is testing

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
MedSIR 486
Large-scale testing (Phase 3)Looking for participantsNCT06757634
What this trial is testing

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Who this might be right for
Breast Cancer
Celcuity Inc 1,180
Testing effectiveness (Phase 2)Study completedNCT02007512
What this trial is testing

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 247
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT06016738
What this trial is testing

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 510
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Study completedNCT01783444
What this trial is testing

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 309
Early research (Phase 1)Study completedNCT04541433
What this trial is testing

AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 10
Large-scale testing (Phase 3)UnknownNCT04753177
What this trial is testing

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Who this might be right for
The Neoadjuvant Therapy
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary 120
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Testing effectiveness (Phase 2)Study completedNCT04489173
What this trial is testing

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Breast NeoplasmChemotherapy Effect
Borstkanker Onderzoek Groep 52
Early research (Phase 1)Study completedNCT01238952
What this trial is testing

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 4
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Ended earlyNCT01071564
What this trial is testing

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+5 more
National Cancer Institute (NCI) 13
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Testing effectiveness (Phase 2)Study completedNCT00834678
What this trial is testing

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Ohio State University Comprehensive Cancer Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Next Page